Business Wire

BALDERTON-CAPITAL

10.6.2021 10:02:29 CEST | Business Wire | Press release

Share
Balderton Capital Expands, Launching $680M ‘Early Growth’ Fund to Invest in Future Tech Giants Born in Europe

Two decades in European tech

After more than 20 years focused on backing Europe’s most ambitious early-stage founders, Balderton Capital is launching a dedicated growth fund to extend its support to European founders scaling the next global tech giants.

While this is the first time the firm has expanded to a completely new stage of primary investing, Balderton already holds one of the largest growth stage portfolios in Europe, having backed some of Europe’s most successful startups from a very early stage. The firm invested at Seed or Series A in global leaders Aircall, ComplyAdvantage, Contentful, Depop, GoCardless, Infarm, Labster, Revolut, THG, Vestiaire Collective and Zego. The firm’s Liquidity I portfolio also includes some of Europe’s leading growth companies, such as Darktrace, Flywire, Graphcore and Truecaller.

Balderton predicts a formidable increase in the European growth stage opportunity

Balderton sees an unprecedented opportunity for growth stage investing in Europe. Along with a maturing technology ecosystem, market disruption caused by the coronavirus pandemic has favoured innovation. The number of deals between $5m and $50m in Europe has been growing steadily year-on-year, with deal counts in those ranges now accelerating faster than in the US. Ten years ago, the US was doing five times the number of venture deals compared to Europe. Today that ratio has more than halved.1 All indications point to more high quality European companies reaching a stage of maturity where they need experienced European growth capital.

“I’ve been an investor at Balderton since 2008, and it has been incredible to see the increasing number of ambitious European founders, and to be able to support them financially through those critical first three to five years with our early stage funds. With this Growth Fund, we can now support them as they scale to become global industry leaders. We predict a $50 billion growth opportunity in Europe in the next three years alone, and we want to be the first choice for those ambitious founders,” said Bernard Liautaud, Managing Partner.

The fund will target exceptional companies at the early-growth stage and is sector-agnostic. Balderton expects to invest between $25m and $50m per company through both primary and secondary investments.

Rana Yared, General Partner, adds: “Our approach for this fund will be ‘one of few’. This means personalised attention from the entire partnership, plus access to Balderton’s leading platform team. We’re looking for fifteen or so really exceptional companies that have the potential to be sector leaders and disrupt global industries.”

World-class growth team

Balderton Growth I will be led by a world-class team of experienced investor operators: Balderton’s Managing Partner, Bernard Liautaud ; General Partner David Thévenon , previously at Google and Softbank; and General Partner Rana Yared , previously at Goldman Sachs. This team brings exceptional experience to share with Founders, having been on the board of global giants across Europe, Asia and the US, including Grab, SoFi, Lemonade, Talend, THG, Tradeweb and Unqork .

Balderton’s Growth team will also be supported by the firm’s equal Partnership . Balderton’s Partners are equally vested in every Portfolio company’s success, and all Founders benefit from access to the full team’s experience and support.

Portfolio leadership teams will also have access to Balderton’s wider team, which has now grown to over 50, including functional specialists in marketing, talent, legal and finance, and 23 investors across key European hubs including London, Berlin, Paris and Stockholm.

David Thévenon, General Partner at Balderton said: “We have been lucky enough to have spent the past two decades deeply embedded in the European tech ecosystem, working with hundreds of extraordinary founders. Our partners are a mixture of financiers, tech operators and founders themselves, and together we have a deep understanding of the opportunities and challenges of scaling globally from the continent. This fund will allow us to expand our support, not only to our existing portfolio but also to Europe’s most promising future global leaders.”

Building on momentum

This fund follows Balderton’s launch of Europe’s first dedicated secondary fund, Liquidity I in 2018, and the firm’s seventh Series A fund in 2019 , and it comes after a record year for both Balderton and its portfolio.

In the 18 months since January 2020, 22 new companies have joined the Balderton portfolio, and the firm has made over 45 follow-on investments. There have been three IPOs, with THG in 2020 , (the second most valuable technology IPO in Europe); Darktrace in 2021 ; and Flywire in 2021 . The firm has also seen eleven portfolio exits since January 2020, including Digital Surgery’s acquisition by Medtronic , Peakon’s acquisition by Workday and Depop’s acquisition by Etsy .

In addition, companies in the Balderton portfolio have themselves raised more than $5bn since January 2020 to fuel growth, of which close to $1.7bn has been since the beginning of 2021. The portfolio now employs over 25,000 staff in over 50 countries around the world.

- ENDS -

About Balderton Capital

Balderton Capital is Europe’s leading venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since its founding, Balderton has worked with hundreds of extraordinary European founders, and has raised 4$bn across nine funds. Previous exited investments include Betfair (FTSE: BET), Depop (Etsy), Digital Surgery (Medtronic), Frontier Car Group (OLX Group), Magic Pony (Twitter), NaturalMotion (Zynga), Peakon (Workday), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Balderton’s current portfolio includes: Aircall, Carwow, Citymapper, Contentful, ComplyAdvantage, Darktrace (LON: DARK), Flywire (NASDAQ: FLYW), GoCardless, Graphcore, Infarm, Kobalt Music, Nutmeg, Prodigy Finance, Revolut, SOPHiA Genetics, Tessian, THG (LON: THG), VanMoof, Vestiaire Collective, Vivino and Zego.

For more information see http://www.balderton.com or follow @balderton.

1 Source: Pitchbook

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye